5.36
price down icon0.56%   -0.03
pre-market  Vorhandelsmarkt:  5.39   0.03   +0.56%
loading
Schlusskurs vom Vortag:
$5.39
Offen:
$5.39
24-Stunden-Volumen:
936.84K
Relative Volume:
0.82
Marktkapitalisierung:
$321.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.80M
KGV:
-7.1467
EPS:
-0.75
Netto-Cashflow:
$-30.67M
1W Leistung:
+7.85%
1M Leistung:
+75.74%
6M Leistung:
+6.56%
1J Leistung:
+38.50%
1-Tages-Spanne:
Value
$5.21
$5.40
1-Wochen-Bereich:
Value
$4.88
$5.6552
52-Wochen-Spanne:
Value
$1.14
$7.20

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name
Firmenname
Aldeyra Therapeutics Inc
Name
Telefon
781-761-4904
Name
Adresse
131 HARTWELL AVENUE, LEXINGTON, MA
Name
Mitarbeiter
8
Name
Twitter
@aldeyraaldx
Name
Nächster Verdiensttermin
2024-11-18
Name
Neueste SEC-Einreichungen
Name
ALDX's Discussions on Twitter

Vergleichen Sie ALDX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALDX
Aldeyra Therapeutics Inc
5.36 297.68M 0 -44.80M -30.67M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-04-03 Hochstufung Oppenheimer Perform → Outperform
2024-04-02 Fortgesetzt H.C. Wainwright Buy
2022-04-27 Fortgesetzt H.C. Wainwright Buy
2021-02-08 Eingeleitet H.C. Wainwright Buy
2020-12-16 Eingeleitet Berenberg Buy
2020-10-30 Eingeleitet Jefferies Buy
2020-10-16 Eingeleitet BTIG Research Buy
2020-09-22 Eingeleitet Alliance Global Partners Buy
2020-05-12 Eingeleitet Oppenheimer Outperform
2018-12-04 Eingeleitet Citigroup Buy
2018-09-26 Bestätigt Cantor Fitzgerald Overweight
2018-09-13 Eingeleitet Janney Buy
2018-01-26 Eingeleitet Seaport Global Securities Buy
2016-09-26 Eingeleitet H.C. Wainwright Buy
2016-07-01 Eingeleitet Stifel Buy
2015-07-01 Eingeleitet Canaccord Genuity Buy
2015-03-25 Eingeleitet Chardan Capital Markets Buy
2015-03-20 Bestätigt H.C. Wainwright Buy
2014-11-18 Eingeleitet H.C. Wainwright Buy
2014-06-19 Eingeleitet Aegis Capital Buy
Alle ansehen

Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten

pulisher
Jul 22, 2025

What analysts say about Aldeyra Therapeutics Inc. stockFree Stock Market Query - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Aldeyra Therapeutics Inc. stock priceHigh-impact stock picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Is Aldeyra Therapeutics Inc. a good long term investmentHigh-octane financial growth - Autocar Professional

Jul 21, 2025
pulisher
Jul 19, 2025

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

FDA accepts Aldeyra's resubmitted reproxalap NDA - Eyes On Eyecare

Jul 18, 2025
pulisher
Jul 17, 2025

FDA accepts for review Aldeyra Therapeutics’ resubmitted new drug application for reproxalap - Optometry Times

Jul 17, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra Therapeutics Announces FDA Acceptance for Review of Repr - GuruFocus

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Lelezard

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Accepts Aldeyra’s Reproxalap Application for Review - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Reviews Aldeyra's (ALDX) Reproxalap for Dry Eye Disease | AL - GuruFocus

Jul 17, 2025
pulisher
Jul 17, 2025

FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug By Investing.com - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 17, 2025

FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Reviews Breakthrough Dry Eye Drug: Aldeyra's Reproxalap Could Transform Treatment Landscape - Stock Titan

Jul 17, 2025
pulisher
Jul 16, 2025

How Aldeyra Therapeutics Inc. stock performs during market volatilityFree Stock Selection - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

why aldeyra therapeutics inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Aldeyra Therapeutics Inc. stock price move sharplyCapital Safe Smart Trades - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Are Medical Stocks Lagging Amgen (AMGN) This Year? - Yahoo Finance

Jul 15, 2025
pulisher
Jul 12, 2025

(ALDX) Trading Report - news.stocktradersdaily.com

Jul 12, 2025
pulisher
Jul 08, 2025

Aldeyra Therapeutics Leads The Pack Among 3 Promising Penny Stocks - simplywall.st

Jul 08, 2025
pulisher
Jul 06, 2025

Market Sentiment Around Loss-Making Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - simplywall.st

Jul 06, 2025
pulisher
Jul 02, 2025

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha

Jul 02, 2025
pulisher
Jun 27, 2025

Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN

Jun 27, 2025
pulisher
Jun 27, 2025

Aldeyra Therapeutics (ALDX) Gets a Buy from JonesTrading - The Globe and Mail

Jun 27, 2025
pulisher
Jun 26, 2025

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma | ALDX Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Aldeyra receives FDA special protocol assessment for lymphoma drug - Investing.com

Jun 26, 2025
pulisher
Jun 26, 2025

Aldeyra receives FDA special protocol assessment for lymphoma drug By Investing.com - Investing.com Canada

Jun 26, 2025
pulisher
Jun 25, 2025

Aldeyra (ALDX) Gains FDA Nod for New Cancer Trial | ALDX Stock N - GuruFocus

Jun 25, 2025
pulisher
Jun 21, 2025

When the Price of (ALDX) Talks, People Listen - news.stocktradersdaily.com

Jun 21, 2025
pulisher
Jun 17, 2025

Aldeyra Therapeutics Resubmits Reproxalap NDA in Dry Eye Disease - HCPLive

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra resubmits NDA for dry eye disease drug after trial success - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra resubmits NDA for dry eye disease drug after trial success By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra Therapeutics (ALDX) Resubmits FDA Application for Dry Ey - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra resubmits Reproxalap's marketing application to FDA - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra Therapeutics Resubmits New Drug Application For Dry Eye Drug; Shares Up Pre-Bell - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application f - GuruFocus

Jun 17, 2025

Finanzdaten der Aldeyra Therapeutics Inc-Aktie (ALDX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):